Beta Drugs Limited

NSEI:BETA 주식 보고서

시가총액: ₹20.6b

Beta Drugs 대차 대조표 상태

재무 상태 기준 확인 6/6

Beta Drugs 의 총 주주 지분은 ₹1.8B 이고 총 부채는 ₹190.6M, 이는 부채 대 자기자본 비율을 10.5% 로 가져옵니다. 총자산과 총부채는 각각 ₹2.9B 및 ₹1.1B 입니다. Beta Drugs 의 EBIT는 ₹558.1M 이며 이자보상배율은 27.2 입니다. ₹278.9M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

10.5%

부채 비율

₹190.60m

부채

이자 보상 비율27.2x
현금₹278.87m
주식₹1.81b
총 부채₹1.14b
총 자산₹2.95b

최근 재무 상태 업데이트

Recent updates

Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Nov 08
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Aug 30
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Aug 30
Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Dec 23
Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Dec 11
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Jul 29
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Jun 17
Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Feb 21
Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Dec 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

Nov 21
With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Sep 02
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

May 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Is Beta Drugs (NSE:BETA) A Risky Investment?

Jan 29
Is Beta Drugs (NSE:BETA) A Risky Investment?

Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Dec 25
Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Nov 20
Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

재무 상태 분석

단기부채: BETA 의 단기 자산 ( ₹2.1B )이 단기 부채( ₹972.5M ).

장기 부채: BETA 의 단기 자산( ₹2.1B )이 장기 부채( ₹164.0M ).


부채 대 자본 내역 및 분석

부채 수준: BETA 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: BETA 의 부채 대 자기자본 비율은 지난 5년간 32.5% 에서 10.5% 로 감소했습니다.

부채 범위: BETA 의 부채는 영업 현금 흐름 ( 132.1% )에 의해 잘 충당되었습니다.

이자 보장: BETA 의 부채에 대한 이자 지급EBIT( 27.2 x 적용 범위)로 잘 충당됩니다.


대차 대조표


건강한 기업 발견하기